Immix Biopharma, Inc. Common Stock
Veridion Score
BETAHIGH CONF · 6/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is IMMX moving today?
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
IMMX overview
Related filings and maps
Congress activity in IMMX
No receipt-qualified Congressional disclosure is present for IMMX in the cached public ledger.
IMMX contract awards, year to date.
Public federal awards linked to this ticker.
IMMX lobbying filings, year to date.
Registered lobbying filings matched to Immix Biopharma, Inc. Common Stock.
CONTINENTAL STRATEGY, LLC
CONTINENTAL STRATEGY, LLC
TARPLIN, DOWNS & YOUNG, LLC